Granules India acquires Swiss Senn Chemicals to foray into peptide and CDMO business
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
We will continue to expand our range of purified excipients, offering pharmaceutical companies a dependable partner
Collaborates with VisionSpring to conduct eye check-up camps for underprivileged children
Revenue from operations also dropped 8.3 per cent at Rs. 133.5 crore in Q3 FY25
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
The Alathur facility specializes in the production of Cephalosporin antibiotics
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Subscribe To Our Newsletter & Stay Updated